Have you incorporated the PCA3 urine test into your practice to help you decide whether to recommend repeat prostate biopsies?
The FDA approved the PCA3 urine test in February 2012 to be used in conjunction with other patient information to help clinicians determine if men who have had a previous negative prostate biopsy should undergo a repeat biopsy.
Although PCA3 has lower sensitivity than PSA, it has higher specificity for prostate cancer as well as superior positive and negative predictive values. Some 20%-40% of men who had initial negative biopsy are found to have an abnormal biopsy on repeat testing.
Renal & Urology News would like to know how urologists have embraced the PCA3 urine test, so please answer the following poll question:
Leave a comment below to explain your choice.